Yükleniyor... / Loading...
This study evaluates the drug PF-04449913 in patients with select advanced blood cancers (hematologic malignancies) that are resistant or intolerant to prior therapies. It included patients for whom standard treatment is not suitable. It was a Phase 1 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Patients with select advanced hematologic malignancies who are refractory, resistant or intolerant to prior therapies. They may be newly diagnosed and previously untreated, but not eligible for standard treatment options, or for whom standard therapies are not anticipated to result in a durable response. * ECOG performance status 0 to 2 * Adequate organ function Exclusion Criteria: * Patients with active CNS disease * Patient with active malignancy with the exception of basal cell carcinoma, non melanoma skin cancer, carcinoma in situ cervical or skin cancer * Active GVHD other than Grade 1 skin involvement * Known malabsorption syndrome * Patient has an active, life threatening or clinically significant uncontrolled systemic infection